Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALM1 | P0DP23 | 1/20 | 0.72 |
| ▸ | IGF1R | P08069 | 1/20 | 0.68 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.68 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | MAOB | P27338 | 2/20 | 0.59 |
| ▸ | IDO1 | P14902 | 1/20 | 0.58 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.58 |
| ▸ | CA1 | P00915 | 1/20 | 0.58 |
| ▸ | CA2 | P00918 | 1/20 | 0.58 |
| ▸ | CA7 | P43166 | 1/20 | 0.58 |
| ▸ | CA9 | Q16790 | 1/20 | 0.58 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.57 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.57 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.55 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.55 |
| ▸ | TUBB | P07437 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11007798 | 0.97 | CALM1 (0.69) | CALM1IGF1RALOX15TAAR1TDP1 | |
| SCHEMBL9509173 | 0.97 | CALM1 (0.69) | CALM1IGF1RALOX15TAAR1TDP1 | |
| SCHEMBL10571532 | 0.97 | CALM1 (0.69) | CALM1IGF1RALOX15TAAR1TDP1 | |
| SCHEMBL17400406 | 0.97 | CALM1 (0.69) | CALM1IGF1RALOX15TAAR1TDP1 | |
| SCHEMBL244070 | 0.95 | CALM1 (0.79) | CALM1IGF1RALOX15TAAR1TDP1 | |
| SCHEMBL10569081 | 0.93 | MAOB (0.70) | CALM1IGF1RALOX15TAAR1TDP1 | |
| SCHEMBL10570923 | 0.91 | CALM1 (0.62) | CALM1IGF1RALOX15TAAR1TDP1 | |
| SCHEMBL10568997 | 0.91 | CASP3 (0.63) | CALM1IGF1RALOX15TAAR1TDP1 | |
| SCHEMBL18857088 | 0.91 | ACHE (0.65) | CALM1IGF1RALOX15TAAR1TDP1 | |
| SCHEMBL581719 | 0.91 | CASP3 (0.63) | CALM1IGF1RALOX15TAAR1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170044121-A1 | TETRA-O-SUBSTITUTED BUTANE-BRIDGE MODIFIED NDGA DERIVATIVES, THEIR SYNTHESIS AND PHARMAECUTICAL USE | ERIMOS PHARMACEUTICALS LLC (US) | 2017-02-16 | — | — | US | disclosed |
| US-9481660-B2 | Tetra-O-substituted butane-bridge modified NDGA derivatives, their synthesis and pharmaceutical use | ERIMOS PHARMACEUTICALS, LLC (US) | 2016-11-01 | — | — | US | disclosed |
| US-20140221384-A1 | TETRA-O-SUBSTITUTED BUTANE-BRIDGE MODIFIED NDGA DERIVATIVES, THEIR SYNTHESIS AND PHARMAECUTICAL USE | ERIMOS PHARMACEUTICALS LLC (US) | 2014-08-07 | — | — | US | disclosed |
| US-8691845-B2 | Tetra-O-substituted butane-bridge modified NDGA derivatives, their synthesis and pharmaceutical use | ERIMOS PHARMACEUTICALS LLC (US) | 2014-04-08 | — | — | US | disclosed |
| EP-2076125-B1 | TETRA-O-SUBSTITUTED BUTANE-BRIDGE MODIFIED NDGA DERIVATIVES, THEIR SYNTHESIS AND PHARMACEUTICAL USE | ERIMOS PHARMACEUTICALS LLC (US) | 2013-12-04 | — | — | EP | disclosed |
| US-20130053378-A1 | TETRA-O-SUBSTITUTED BUTANE-BRIDGE MODIFIED NDGA DERIVATIVES, THEIR SYNTHESIS AND PHARMACEUTICAL USE | ERIMOS PHARMACEUTICALS LLC (US) | 2013-02-28 | — | — | US | disclosed |
| US-8232277-B2 | Tetra-O-substituted butane-bridge modified NDGA derivatives, their synthesis and pharmaceutical use | ERIMOS PHARMACEUTICALS LLC (US) | 2012-07-31 | — | — | US | disclosed |
| US-20090306070-A1 | TETRA-O-SUBSTITUTED BUTANE-BRIDGE MODIFIED NDGA DERIVATIVES, THEIR SYNTHESIS AND PHARMACEUTICAL USE | ERIMOS PHARMACEUTICALS LLC (US) | 2009-12-10 | — | — | US | disclosed |
| EP-2076125-A2 | TETRA-O-SUBSTITUTED BUTANE-BRIDGE MODIFIED NDGA DERIVATIVES, THEIR SYNTHESIS AND PHARMACEUTICAL USE | Erimos Pharmaceuticals LLC (US) | 2009-07-08 | — | — | EP | disclosed |
| WO-2008042921-A2 | TETRA-O-SUBSTITUTED BUTANE-BRIDGE MODIFIED NDGA DERIVATIVES, THEIR SYNTHESIS AND PHARMACEUTICAL USE | ERIMOS PHARMACEUTICALS LLC (US) | 2008-04-10 | — | — | WO | disclosed |
| EP-0840606-B1 | DI- AND TRIVALENT SMALL MOLECULE SELECTIN INHIBITORS | TEXAS BIOTECHNOLOGY CORP (US) | 2000-06-07 | — | — | EP | disclosed |
| US-5919768-A | COMPOUNDS WHICH INHIBIT BINDING OF SELECTINS TO SIALYL-LEWIS-X AND SIALYL-LEWIS-A CARBOHYDRATES | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1999-07-06 | — | — | US | disclosed |
| US-4834905-A | LIQUID CRYSTAL DIELECTRICS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1989-05-30 | — | — | US | disclosed |
| US-4627933-A | ESTERS, ETHERS, NITRICES, HALIDES, OR HYDROCARBONS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1986-12-09 | — | — | US | disclosed |
| EP-0104327-A2 | Use of cyclic derivatives as components of liquid cristals | MERCK PATENT GmbH (DE) | 1984-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044121-A1 | TETRA-O-SUBSTITUTED BUTANE-BRIDGE MODIFIED NDGA DERIVATIVES, THEIR SYNTHESIS AND PHARMAECUTICAL USE | PTGES, HPGDS, HPGD | CALM1 3946/4885IGF1R 1711/4885ALOX15 185/4885 |
| US-20090306070-A1 | TETRA-O-SUBSTITUTED BUTANE-BRIDGE MODIFIED NDGA DERIVATIVES, THEIR SYNTHESIS AND PHARMACEUTICAL USE | PTGES, HPGDS, HPGD | CALM1 3890/4885IGF1R 1538/4885ALOX15 171/4885 |
| US-20140221384-A1 | TETRA-O-SUBSTITUTED BUTANE-BRIDGE MODIFIED NDGA DERIVATIVES, THEIR SYNTHESIS AND PHARMAECUTICAL USE | PTGES, HPGDS, HPGD | CALM1 3946/4885IGF1R 1711/4885ALOX15 185/4885 |
| US-20130053378-A1 | TETRA-O-SUBSTITUTED BUTANE-BRIDGE MODIFIED NDGA DERIVATIVES, THEIR SYNTHESIS AND PHARMACEUTICAL USE | PTGES, HPGDS, HPGD | CALM1 3890/4885IGF1R 1538/4885ALOX15 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.